Allspring Global Investments Holdings LLC Sells 220,467 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Allspring Global Investments Holdings LLC cut its position in shares of Dynavax Technologies Co. (NASDAQ:DVAXGet Rating) by 65.6% during the 3rd quarter, Holdings Channel reports. The firm owned 115,684 shares of the biopharmaceutical company’s stock after selling 220,467 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Dynavax Technologies were worth $1,207,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DVAX. Advisors Asset Management Inc. boosted its stake in Dynavax Technologies by 498.0% in the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 1,967 shares during the last quarter. Quantbot Technologies LP lifted its stake in shares of Dynavax Technologies by 940.7% during the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 2,267 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Dynavax Technologies during the 2nd quarter valued at approximately $67,000. Point72 Hong Kong Ltd purchased a new stake in shares of Dynavax Technologies during the 1st quarter valued at approximately $102,000. Finally, Captrust Financial Advisors lifted its stake in shares of Dynavax Technologies by 1,116.0% during the 2nd quarter. Captrust Financial Advisors now owns 10,336 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 9,486 shares in the last quarter. 94.26% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Dynavax Technologies

In related news, COO David F. Novack sold 52,204 shares of the stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $12.47, for a total transaction of $650,983.88. Following the transaction, the chief operating officer now owns 2,066 shares of the company’s stock, valued at approximately $25,763.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Dynavax Technologies news, Director Andrew A. F. Hack sold 1,500,000 shares of the stock in a transaction on Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the completion of the sale, the director now owns 3,915,000 shares of the company’s stock, valued at approximately $45,414,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO David F. Novack sold 52,204 shares of the stock in a transaction on Tuesday, November 8th. The shares were sold at an average price of $12.47, for a total transaction of $650,983.88. Following the sale, the chief operating officer now directly owns 2,066 shares of the company’s stock, valued at approximately $25,763.02. The disclosure for this sale can be found here. 9.31% of the stock is owned by insiders.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $11.30 on Friday. The company’s fifty day moving average price is $11.54 and its 200-day moving average price is $12.15. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 5.46 and a beta of 1.37. Dynavax Technologies Co. has a one year low of $7.26 and a one year high of $17.48. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.82 and a quick ratio of 3.40.

Dynavax Technologies (NASDAQ:DVAXGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.10. The firm had revenue of $167.74 million for the quarter, compared to analyst estimates of $149.99 million. Dynavax Technologies had a net margin of 44.35% and a return on equity of 90.54%. On average, equities research analysts anticipate that Dynavax Technologies Co. will post 1.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on DVAX shares. JMP Securities started coverage on shares of Dynavax Technologies in a research note on Tuesday, September 27th. They set an “outperform” rating and a $22.00 price target on the stock. The Goldman Sachs Group decreased their target price on shares of Dynavax Technologies from $24.00 to $21.00 and set a “buy” rating on the stock in a report on Friday, November 4th. Finally, StockNews.com lowered shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Monday, November 7th.

Dynavax Technologies Profile

(Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Stories

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAXGet Rating).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.